⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1870032 | 0.60 | — | — | |
| SCHEMBL3799503 | 0.60 | PTPRC (0.34) | — | |
| SCHEMBL4066311 | 0.58 | — | — | |
| SCHEMBL7229747 | 0.58 | — | — | |
| SCHEMBL2439807 | 0.52 | — | — | |
| SCHEMBL31185550 | 0.51 | S100A4 (0.36) | — | |
| SCHEMBL31511817 | 0.47 | S100A4 (0.54) | — | |
| SCHEMBL7719621 | 0.47 | S100A4 (0.54) | — | |
| SCHEMBL17581080 | 0.47 | — | — | |
| SCHEMBL13010024 | 0.47 | ALDH1A1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE39679-E1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-06-05 | — | — | US | claimed |
| US-RE39680-E1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-06-05 | — | — | US | claimed |
| US-7081455-B2 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-25 | — | — | US | claimed |
| US-7071186-B2 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA CO. (US) | 2006-07-04 | — | — | US | claimed |
| US-20040220178-A1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-11-04 | — | — | US | claimed |
| US-20040209864-A1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-10-21 | — | — | US | claimed |
| EP-1189905-B1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-09-29 | — | — | EP | claimed |
| EP-1189904-B1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-09-22 | — | — | EP | claimed |
| US-20040127482-A1 | Administering substituted heterocycle fused gamma-carboline compounds for therapy of addictive behavior associated with 5HT2C receptor modulation | ROBICHAUD ALBERT J (US) | 2004-07-01 | — | — | US | claimed |
| US-6713471-B1 | SUCH AS TERT-BUTYL-1-METHYL-6,7,9,12-TETRAHYDRO-5H-PYRIDO-(4,3-B)(1,4) THIAZEPINO(2,3,4-HI)INDOLE-11(10H)-CARBOXYLATE; SEROTONIN AGONISTS AND ANTAGONISTS; CENTRAL NERVOUS SYSTEM DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-30 | — | — | US | claimed |
| US-6548493-B1 | Serotonin receptor modulators (5-HT2C and 5-HT2A); treating obesity, anxiety, depression, psychological disorders, migraine, sexual disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-15 | — | — | US | claimed |
| JP-2003502336-A | — | — | 2003-01-21 | — | — | JP | claimed |
| JP-2003502331-A | — | — | 2003-01-21 | — | — | JP | claimed |
| JP-2003502330-A | — | — | 2003-01-21 | — | — | JP | claimed |
| EP-1192165-A2 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | Bristol-Myers Squibb Pharma Company (US) | 2002-04-03 | — | — | EP | claimed |
| EP-1189905-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | Bristol-Myers Squibb Pharma Company (US) | 2002-03-27 | — | — | EP | claimed |
| EP-1189904-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | Bristol-Myers Squibb Pharma Company (US) | 2002-03-27 | — | — | EP | claimed |
| WO-2000077010-A2 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-12-21 | — | — | WO | claimed |
| WO-2000077001-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-12-21 | — | — | WO | claimed |
| WO-2000077002-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-12-21 | — | — | WO | claimed |